Life Technologies (LIFE) is coordinating wet lab applications with software and bioinformatics tools to model, design, and validate organisms engineered through synthetic biology approaches. These research applications will enhance understanding the biology of organisms while engineering them in a more controlled way. This approach has applications in material sciences, metabolic engineering, the study and treatment of disease and basic biology.
Simplifying and productizing synthetic biology leads to a series of ethical issues for LIFE . We can engineer genomes now, not just genes. As a public company LIFE delivers share holder value, so support of science is based on successful commercial outcomes. Rational design tools and solutions of biological organisms will allow more people to analyze and engineer genetically manipulated organisms in a global market.
Clancy will describe LIFE’s current commercial approach to research, development and distribution of technologies, comparing and contrasting with academic concerns and practices. He will give examples of how LIFE interacts with and contributes nationally and internationally to bioethical issue identification, problem solving and biosecurity.
He will contrast the desire for enhancing biosecurity screening with privacy concerns and the risks of stifling innovation in this nascent field.
Please visit our website for more information